Suppliers and packagers for generic pharmaceutical drug: abacavir sulfate; dolutegravir sodium; lamivudine

abacavir sulfate; dolutegravir sodium; lamivudine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413	NDA	ViiV Healthcare Company	49702-258-37	1 KIT in 1 CARTON (49702-258-37) * 90 TABLET, FILM COATED in 1 BOTTLE (49702-272-59)	2022-03-30
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551	NDA	ViiV Healthcare Company	49702-231-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-231-13)	2014-08-22

Suppliers and packagers for generic pharmaceutical drug: abacavir sulfate; dolutegravir sodium; lamivudine

Last updated: June 1, 2026

Suppliers for Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine (API and Finished Dosage)

Executive summary: Global supply is split between (1) API manufacturers for each active ingredient (abacavir sulfate, dolutegravir sodium, lamivudine) and (2) finished-dose packers and originator/generic companies that buy APIs and commercialize fixed-dose combinations (FDCs) and co-packaged products. Procurement and IP diligence typically hinge on API DMFs/CEP status, route-of-synthesis comparability, and whether the final product is a licensed FDC versus single-ingredient tablets.

Which companies supply abacavir sulfate API for generic and FDC production?

Featured-snippet answer: Abacavir sulfate API supply is dominated by Indian and Chinese API manufacturers plus a smaller set of Western firms; sourcing is typically validated through DMF holders and inspection-ready manufacturing sites.

Common abacavir sulfate API supplier archetypes

• DMF/CEP holders supplying to global generic packers.
• Contract manufacturers that produce abacavir sulfate under API supply agreements to downstream marketers.
• FDC manufacturers that vertically integrate API production for fixed-dose abacavir-based combinations (varies by region and product).

What to verify for abacavir sulfate sourcing

• DMF status (active, referenced, and suitability for the target dossier).
• Site inspection readiness (FDA, EMA, and local authority track record).
• Co-crystal/grade and specifications aligned to tablet formulation requirements (impurity profile and particle characteristics).

Which companies supply dolutegravir sodium API?

Featured-snippet answer: Dolutegravir sodium API is supplied by a narrower, more quality-controlled set of manufacturers because it has tighter regulatory and commercial scrutiny versus legacy APIs, especially for first-line HIV regimens.

Typical dolutegravir sodium supply channels

• API manufacturers with DMFs used by multi-market generic formulators.
• Licensed supply arrangements where downstream product teams must match specific synthetic routes and impurity specs.
• Batch-size flexible producers used for tender-based procurement.

What to verify for dolutegravir sodium sourcing

• Impurity control tied to dolutegravir regulatory specifications.
• Polymorph/hydrate/solid-state behavior stability for downstream blending and tableting.
• Stability and packaging compatibility for FDC manufacturing schedules.

Which companies supply lamivudine API for HIV combination therapies?

Featured-snippet answer: Lamivudine API supply is broad, with multiple qualified manufacturers across India and China, plus occasional Western suppliers for premium or inspection-sensitive tenders.

Lamivudine supply characteristics

• Higher supplier breadth than dolutegravir sodium.
• More established procurement frameworks due to longer market history.
• Multiple spec frameworks (pharmacopoeial and dossier-specific).

What to verify for lamivudine sourcing

• Impurity profile (including related substances).
• Particle size distribution and flow properties impacting manufacturability.
• Doc readiness (DMF/COA consistency across lots).

How do suppliers differ for single-ingredient products vs fixed-dose combinations (FDCs)?

Featured-snippet answer: Single-ingredient tablets often use commodity-like API procurement, while FDCs require stronger control on API grades, CoA alignment, and synchronized batch release schedules across all actives.

Key differences

• API grade alignment: FDCs require consistent grade/spec matching across abacavir sulfate, lamivudine, and dolutegravir sodium.
• Release timing: FDC packaging schedules force tighter lead times.
• Regulatory strategy: Some FDCs are marketed as “authorized generics” or rely on reference product manufacturing knowledge, limiting supplier switching.

What are the main finished-dose makers that buy these APIs (U.S./EU/global coverage)?

Featured-snippet answer: Finished-dose market participants include (1) originator supply chains and (2) generic packers that source APIs from qualified DMF holders and manufacture tablets under local market authorizations.

Finished-dose procurement model

• API manufacturers sell to multiple packers.
• Packers manage formulation, bioequivalence strategy, and regulatory filings.
• Local license holders can act as marketing authorizations and importers.

What suppliers are typically used for HIV regimens combining abacavir, dolutegravir, and lamivudine?

Featured-snippet answer: In practice, the selection is driven by which FDC or co-pack combination is being produced in the target jurisdiction, because supplier qualification is tied to the dossier and manufacturing site, not just the API name.

Procurement implications

• If the target is an FDC tablet, supplier qualification must cover all three actives and the specific batch release sequence.
• If the target is co-packaged single ingredients, suppliers may vary by active ingredient and lot schedule, but procurement still requires dossier-compatible specs.

How does DMF status determine which API suppliers can be used?

Featured-snippet answer: The “right” supplier is the one whose API documentation is already referenced in the target market filings or can be readily bridged into new submissions.

DMF-driven constraints

• Letter of Authorization (LoA) arrangements for DMF access.
• Site-specific manufacturing controls required for equivalence.
• Cross-market dossier compatibility where the same API spec is used across regions.

What packaging and supply logistics matter for these HIV APIs?

Featured-snippet answer: For all three APIs, logistics matter less in the cold chain sense and more in spec retention: moisture control, impurity creep control, and batch traceability.

Critical logistics checks

• Moisture and stability (especially for long lead-time tenders).
• Temperature excursion history documentation for shipping.
• Traceability from API batch to finished-dose blend record.

Which regulatory filings influence supplier selection (DMF, CEP, and inspections)?

Featured-snippet answer: Supplier selection hinges on dossier acceptability (DMF referenced in the finished-dose submission), plus inspectability of the manufacturing site.

Regulatory diligence points

• DMF referenceability for the target country authority.
• Inspection outcomes and remediation history.
• Change control track record for synthetic route and impurity profile changes.

What generic entry risks exist for switching API suppliers mid-stream?

Featured-snippet answer: Changing API suppliers can trigger regulatory comparability work, with risks of delays if impurities or solid-state profiles shift and cannot be bridged to prior submissions.

Risk drivers

• Impurity profile drift versus dossier specifications.
• Solid-state differences (particle size, polymorph, hydration behavior).
• CMC change timing that misses product release windows.

Key Takeaways

• Supply chains for abacavir sulfate, dolutegravir sodium, and lamivudine are structured around API DMF/inspection readiness and finished-dose dossier compatibility.
• Supplier switching is feasible in principle but constrained by impurity specs, solid-state behavior, and dossier referencing.
• For FDC regimens, supplier qualification must support synchronized batch release and consistent CoAs across all actives.
• Procurement should be organized around DMF access, manufacturing site audit readiness, and comparability risk rather than API name alone.

FAQs

1. How do I qualify an alternative supplier for abacavir sulfate without delaying tablet release schedules?
2. Does dolutegravir sodium supplier choice affect impurity profiles more than lamivudine?
3. What documentation is usually required to change an API supplier for an FDC containing abacavir, dolutegravir, and lamivudine?
4. What manufacturing inspection standards most influence API supplier approval for HIV regimens?
5. How do DMF Letter of Authorization and site-specific controls impact the ability to use new API sources?

References

1. FDA. Drug Master Files (DMFs) Overview. U.S. Food and Drug Administration.
2. EMA. Regulatory Framework for DMFs and Data Submission/Assessment (guidance and procedural documents). European Medicines Agency.
3. ICH. Q8/Q9/Q10 and CMC guidance documents (quality risk management, pharmaceutical development, pharmaceutical quality system). International Council for Harmonisation.